NASDAQ:OPNT - Opiant Pharmaceuticals News Headlines

Sign in or create an account to add this stock to your watchlist.
$15.90 -0.06 (-0.38 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$15.96
Today's Range$15.30 - $16.00
52-Week Range$12.75 - $32.28
Volume5,977 shs
Average Volume39,208 shs
Market Capitalization$61.08 million
P/E Ratio5.41
Dividend YieldN/A
Beta0.27

Headlines

Opiant Pharmaceuticals (NASDAQ OPNT) News Headlines

Source:
DateHeadline
Phil Skolnick Sells 4,321 Shares of Opiant Pharmaceuticals Inc (OPNT) StockPhil Skolnick Sells 4,321 Shares of Opiant Pharmaceuticals Inc (OPNT) Stock
www.americanbankingnews.com - December 6 at 8:08 PM
 Opiant Pharmaceuticals Inc (OPNT) Receives Average Recommendation of "Strong Buy" from Brokerages Opiant Pharmaceuticals Inc (OPNT) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 25 at 1:34 PM
Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?Does Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) CEO Salary Reflect Performance?
finance.yahoo.com - November 20 at 5:14 PM
New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained ProductionNew Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
finance.yahoo.com - November 19 at 8:24 AM
OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…OPNT: Data from Phase 2 Study of OPNT001 in Bulimia Nervosa in 1Q19…
finance.yahoo.com - November 8 at 5:31 PM
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 5:39 PM
Opnet Technologies, Inc. (OPNT) Reports Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia NervosaOpnet Technologies, Inc. (OPNT) Reports Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
www.streetinsider.com - November 6 at 8:26 AM
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia NervosaOpiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
finance.yahoo.com - November 5 at 9:01 AM
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on ...Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on ...
globenewswire.com - November 2 at 5:15 PM
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7thOpiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
finance.yahoo.com - November 1 at 8:17 AM
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of DirectorsOpiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
finance.yahoo.com - October 29 at 8:28 AM
Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry DayOpiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
finance.yahoo.com - October 22 at 8:26 AM
Opiant Pharmaceuticals OPNT005 receives grant for development of a heroin vaccineOpiant Pharmaceuticals' OPNT005 receives grant for development of a heroin vaccine
seekingalpha.com - October 18 at 5:01 PM
Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin VaccineOpiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine
finance.yahoo.com - October 18 at 8:36 AM
OPNT: Contract with BARDA to Support Develop of OPNT003…OPNT: Contract with BARDA to Support Develop of OPNT003…
finance.yahoo.com - October 4 at 4:49 PM
Opiant nets $12.7M in equity offeringOpiant nets $12.7M in equity offering
seekingalpha.com - September 28 at 4:55 PM
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesOpiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - September 28 at 4:55 PM
Opiant Pharmaceuticals to Present at the Cantor Global Healthcare ConferenceOpiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
finance.yahoo.com - September 26 at 8:36 AM
Opiant prices stock offering at $17; shares down 19% premarketOpiant prices stock offering at $17; shares down 19% premarket
seekingalpha.com - September 25 at 4:55 PM
Opiant Pharmaceuticals Announces Pricing of Public Offering of Common StockOpiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - September 25 at 4:55 PM
Opiant Pharmaceuticals Announces Proposed Public Offering of Common StockOpiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
finance.yahoo.com - September 24 at 4:54 PM
Opiant nabs BARDA funding up to $4.6M for opioid overdose med; shares up 7% after hoursOpiant nabs BARDA funding up to $4.6M for opioid overdose med; shares up 7% after hours
seekingalpha.com - September 21 at 8:30 AM
Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - September 20 at 4:51 PM
How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?How Should You Think About Opiant Pharmaceuticals Inc’s (NASDAQ:OPNT) Risks?
finance.yahoo.com - September 14 at 4:55 PM
Opnet Technologies, Inc. (OPNT) Reports Manufacturing Pact with Consort Medical Plc for OPNT003Opnet Technologies, Inc. (OPNT) Reports Manufacturing Pact with Consort Medical Plc for OPNT003
www.streetinsider.com - September 12 at 8:26 AM
Opiant Pharmaceuticals signs manufacturing agreement with Consort Medical for OPNT003 for treatment of opioid overdoseOpiant Pharmaceuticals signs manufacturing agreement with Consort Medical for OPNT003 for treatment of opioid overdose
seekingalpha.com - September 10 at 4:52 PM
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - September 10 at 8:30 AM
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia NervosaOpiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
globenewswire.com - September 5 at 8:32 AM
UPDATE: Opiant Pharmaceuticals, Inc. (OPNT) Reports Final Patient Enrolled in Phase 2 Clinical Trial Evaluating ...UPDATE: Opiant Pharmaceuticals, Inc. (OPNT) Reports Final Patient Enrolled in Phase 2 Clinical Trial Evaluating ...
www.streetinsider.com - September 4 at 5:02 PM
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia ...Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia ...
www.nasdaq.com - September 4 at 8:34 AM
Opiant Pharma up 73% premarket on EBS takeout of Adapt PharmaOpiant Pharma up 73% premarket on EBS takeout of Adapt Pharma
seekingalpha.com - August 29 at 4:54 PM
OPNT: Adapt Pharma® Acquired for $650 Million…OPNT: Adapt Pharma® Acquired for $650 Million…
finance.yahoo.com - August 29 at 4:54 PM
Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of InfluenceInvestor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Factors of Influence
finance.yahoo.com - August 16 at 8:31 AM
Opiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q2 2018 Results - Earnings Call TranscriptOpiant Pharmaceuticals, Inc. (OPNT) CEO Dr. Roger Crystal on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 15 at 8:32 AM
OPNT: Increasing Royalties from NARCAN® Nasal Spray…OPNT: Increasing Royalties from NARCAN® Nasal Spray…
finance.yahoo.com - August 10 at 5:16 PM
Opiant Pharmaceuticals, Inc. to Host Earnings CallOpiant Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 5:47 PM
Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - August 9 at 5:47 PM
Opiant up 36% premarketOpiant up 36% premarket
seekingalpha.com - August 4 at 9:46 AM
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on ...Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on ...
globenewswire.com - August 2 at 5:21 PM
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9
finance.yahoo.com - August 2 at 8:32 AM
Opiant Pharma up 20% premarketOpiant Pharma up 20% premarket
seekingalpha.com - July 12 at 4:42 PM
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid OverdoseOpiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
finance.yahoo.com - June 25 at 5:27 PM
Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International ConventionOpiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
finance.yahoo.com - June 4 at 5:05 PM
Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual MeetingOpiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
finance.yahoo.com - May 29 at 8:32 AM
Report: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - May 25 at 8:27 AM
OPNT: KOL Event Highlights Medications for Addictions and Related DisordersOPNT: KOL Event Highlights Medications for Addictions and Related Disorders
finance.yahoo.com - May 15 at 5:41 PM
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate UpdateOpiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 8 at 5:28 PM
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related DisordersOpiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
finance.yahoo.com - May 3 at 8:26 AM
Blog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid OverdoseBlog Exposure - Opiant Pharma Receives Grant for Development of OPNT003 for Treatment of Opioid Overdose
finance.yahoo.com - April 20 at 8:36 AM
Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ...Opiant Pharmaceuticals Awarded Grant of Approximately $7.4 Million from the National Institutes of Health for ...
globenewswire.com - April 19 at 8:26 AM
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Featured Article: Systematic Risk

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel